Skip to main
BSX

Boston Scientific (BSX) Stock Forecast & Price Target

Boston Scientific (BSX) Analyst Ratings

Based on 22 analyst ratings
Buy
Strong Buy 45%
Buy 45%
Hold 9%
Sell 0%
Strong Sell 0%

Bulls say

Boston Scientific is a leading medical device company with a diverse product portfolio and a global presence. Their focus on less invasive medical devices gives them a competitive edge in the market, and their recent M&A activity shows potential for future growth. However, there are risks such as stiffer macroeconomic headwinds and potential challenges with their WATCHMAN product line. Despite these risks, Boston Scientific's current valuation appears accommodating, making it an attractive investment opportunity with potential for upside in the future.

Bears say

Boston Scientific is a company that specializes in manufacturing and marketing medical devices for various procedures, including coronary IVL, interventional oncology, and neuromodulation. The company has a global reach and has been facing challenges in its WATCHMAN sales. The company's risks include competition, market share loss, and potential regulatory delays. Despite these challenges, Boston Scientific's diverse product portfolio and cost reduction efficiencies should lead to double-digit earnings growth. However, the potential for slower electrophysiology and WATCHMAN sales could be a risk to the company's growth targets. As a result, the company's forecasted earnings for 2027 have been adjusted and we have lowered our price target to $57 from $77.

Boston Scientific (BSX) has been analyzed by 22 analysts, with a consensus rating of Buy. 45% of analysts recommend a Strong Buy, 45% recommend Buy, 9% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Boston Scientific and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Boston Scientific (BSX) Forecast

Analysts have given Boston Scientific (BSX) a Buy based on their latest research and market trends.

According to 22 analysts, Boston Scientific (BSX) has a Buy consensus rating as of Sep 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $70.23, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $70.23, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Boston Scientific (BSX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.